About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Test Developed to Enable Personalized Treatment of Inflammatory Bowel Disease

by Colleen Fleiss on May 4, 2019 at 7:04 PM
Font : A-A+

New Test Developed to Enable Personalized Treatment of Inflammatory Bowel Disease

University of Cambridge scientists have developed a novel test that predicts the future course of inflammatory bowel disease in people, transforming treatments for patients and paving the way for a personalised approach.

Ulcerative colitis and Crohn's disease - collectively known as inflammatory bowel disease (IBD) - are chronic conditions that involve inflammation of the gut. Symptoms include abdominal pain, bloody diarrhoea, weight loss and fatigue. There is currently no cure, but there are a growing number of medicines that aim to relieve symptoms and prevent the condition returning; however, the more severe the case of the IBD, the stronger the drugs need to be and the greater the potential side effects.

Advertisement


Researchers at the Department of Medicine, University of Cambridge, and Cambridge University Hospitals NHS Trust previously showed that a genetic signature found in a certain type of immune cell known as a CD8 T-cell could be used to assign patients to one of two groups depending on whether their condition was likely to be mild or severe (requiring repeated treatment). However, isolating CD8 T- cells and obtaining the genetic signature was not straightforward, making the test unlikely to be scaleable and achieve widespread use. In the latest study, published in the journal Gut, the researchers worked with a cohort of 69 patients with Crohn's disease to see whether it was possible to develop a useful, scaleable test by looking at whole blood samples in conjunction with CD8 T-cells and using widely-available technology.

The team used a combination of machine learning and a whole blood assay known as qPCR - a relatively simple tool used in NHS labs across the country - to identify genetic signatures that re-created the two subgroups from their previous study.
Advertisement

The researchers then validated their findings in 123 IBD patients recruited from clinics in Cambridge, Nottingham, Exeter and London.

"This is important as it could enable doctors to personalise the treatment that they give to each patient. If an individual is likely to have only mild disease, they don't want to be taking strong drugs with unpleasant side-effects. But similarly, if someone is likely to have a more aggressive form of the disease, then the evidence suggests that the sooner we can start them on the best available treatments, the better we can manage their condition." The accuracy of the test is comparable to similar biomarkers used in cancer, which have helped transform treatment, say the researchers. They found the new test was 90-100% accurate in correctly identifying patients who did not require multiple treatments.

"IBD can be a very debilitating disease, but this new test could help us transform treatment options, moving away from a 'one size fits all' approach to a personalised approach to treating patients," says Professor Ken Smith, senior author and Head of the Department of Medicine. The test is now being developed further by PredictImmune, a spinout company co-founded by Professor Smith with support from Cambridge Enterprise, the University's technology transfer arm. The team is involved in a £4.2 million trial to see whether using the biomarker to guide treatment at the time of diagnosis can lead to better outcomes for patients.

The findings have been welcomed by Helen Terry, Director of Research at Crohn's & Colitis UK, which helps fund the research. "It's really exciting that we are moving away from a 'one size fits all' approach for people with Crohn's or Colitis. Dr Lee and his team's latest study is the accumulation of 10 years' worth of research and we're now at the stage where this test will be available in the NHS. This could drastically change the lives of people with Crohn's or Colitis as it means they can be started on the best medication for them sooner."

Additional funding for the research came from Wellcome, the Medical Research Council and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre.

Later this year, Professor Smith and his team are due to move into the new Cambridge Institute of Therapeutic Immunology and Infectious Disease, to be based in the Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus, the centrepiece of the largest biotech cluster outside the United States.

Case study: Kate Gray, aged 31, Amersham, living with Crohn's Kate was diagnosed with Crohn's Disease when she was 14 years old having been unwell with symptoms for quite some time.

This meant she needed surgery. "I was told by my consultant I would only need a little bit of a resection and that it's unlikely I would be bothered by symptoms for decades, giving me the impression that was probably the end of it."

Within 9 months of her bowel resection, Kate's symptoms had returned. She tried various medications, including immunosuppressants and steroids but nothing worked, and she kept getting more unwell. She also had some nasty side effects from the drug mercaptopurine, becoming neutropaenic (low on neutrophils), leading to two admissions to hospital.

This pathway continued throughout Kate's secondary education and once on the drug infliximab, it reached the point where Kate couldn't eat solid foods. Her bowel was so strictured and damaged that she was told she needed an ileostomy at the age of 20. In the lead-up to this Kate had a nasal-gastric feeding tube which involved long stints in hospital.

When Kate woke up from her operation, she was told that the damage was much more extensive than thought and she would have a permanent stoma.

Following surgery, Kate was started on the biologic drug, Humira and has been on this weekly ever since. "My stoma's been amazing and bowel wise, my symptoms have been good for the past decade."

Kate could have benefited hugely from a prognostic test, making her more aware of disease course and allowing her to try stronger treatments earlier.

"I do sometimes wonder what would have happened if I knew my disease was going to be more severe and not mild, as I was told. It's likely I would have opted for my ileostomy sooner and would have been keen to try stronger drugs earlier as this might have halted to progression of my Crohn's. It would also have been good to have known what other symptoms I could have expected with more severe Crohn's, including issues with my joints, uveitis and Crohn's on the skin at the site of my surgery scars."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Ways to Manage Stress during COVID-19 Pandemic
Can Adjusting Fatty Acid Intake Improve Mood in Bipolar Disorder Patients?
Insulin Resistance Doubles the Risk of Major Depressive Disorder
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Colo-rectal cancer - Management Undescended Testicles Varicocele Crohns Disease Testicle Pain - Symptom Evaluation Torsion Testis Inflammatory Bowel Disease Orchidectomy Foul Smelling Stool 

Recommended Reading
Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) causes recurrent abdominal pain or discomfort and a fluctuating ......
Quiz on Irritable Bowel Syndrome
Frequent bowel disturbances are a sign of possible cancerous changes; Here's a quiz to help you ......
Irritable Bowel Syndrome Awareness Month – Let Us Speak Out
Irritable bowel syndrome (IBS) awareness month is observed in April and aims to raise awareness ......
Irritable Bowel Syndrome Diagnosed by Listening to Gut Noises
Irritable Bowel Syndrome (IBS) can now be diagnosed by a machine learning-based acoustic belt that ....
Colo-rectal cancer - Management
Treatment for Colorectal Cancers may involve surgery,chemotherapy, radiation therapy or biological t...
Crohns Disease
Crohn’s disease or regional enteritis is an inflammatory bowel disease that involves the small intes...
Foul Smelling Stool
Foul smelling stool is a stool that has a bad odor. Poor diet and indigestion are the most common ca...
Inflammatory Bowel Disease
Inflammatory bowel disease involves chronic inflammation of the colon and small intestine. Symptoms ...
Testicle Pain - Symptom Evaluation
A sudden, severe pain in the testis may be due to testicular torsion. Testicles inside the scrotum a...
Torsion Testis
Torsion occurs when the testis spins, twisting the spermatic cord, causing reduced blood flow and te...
Undescended Testicles
An undescended testicle / testis is one that has not descended into the scrotal sac before birth. It...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use